The clinical evidence and the role of imiquimod in the extramammary Paget disease by Christos Iavazzo et al.
103ACTA DERMATOVENEROLOGICA CROATICA
The Clinical Evidence and the Role of Imiquimod in the 
Extramammary Paget Disease
Christos Iavazzo1, Fotinie Ntziora2, Charalampos Karachalios3, Paraskevi 
Evangelia Iavazzo4, Ioannis D. Gkegkes5 
1Iaso Maternity Hospital, Athens, 21st Department of Medicine, Laiko General Hospital, 
Athens, 3Department of Surgery, Elena Venizelou Hospital, Athens, 4Rural Practice, Mo-
los, Fthiotida, 5Department of Surgery, Korinthos General Hospital, Corinth, Greece
Corresponding author: 
Christos Iavazzo, MD, MSc, PhD




Received: October 11, 2013
Accepted: February 15, 2014
InTRoDuCTIon
Extramammary Paget disease is an infrequent cu-
taneous neoplasm of the apocrine gland-bearing vul-
var or scrotum skin with an unknown etiology (1,2). 
It represents less than 1% of vulvar neoplasms (3,4). 
The presentation is variable and non-specific. Most 
commonly, it presents as an intraepithelial adenocar-
cinoma in situ, and rarely as the pagetoid spread of 
an underlying regional internal malignancy (5,6). It 
clinically presents as an erythematous, eczematous, 
pruriginous, and sometimes painful plaque with a 
scaly grayish well demarcated crust with erosion and 
ulceration on its surface (7,8). For this reason, it may 
be mistaken for other skin conditions, such as inflam-
matory diseases or infections, which can lead to a 
delay in diagnosis and treatment (9). It usually affects 
postmenopausal women between 50 and 80 years of 
age or men in their seventh decade of life, predomi-
nantly of Caucasian origin.
The first-line therapeutic option for extramam-
mary Paget disease is wide surgical excision with 
microscopically clear margins (10). However, surgical 
treatment is characterized by high recurrence rates, 
between 20-50% (2). Mohs microscopically controlled 
surgery seems to be an alternative treatment with 
significantly lower recurrence rates than wide local 
excision  (45). Furthermore, not all patients are capa-
ble of undergoing an operation due to comorbidities, 
and some of them may opt out (11). Other treatment 
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SuMMARY Extramammary Paget disease is a rare disease. Different treat-
ment options are used for its management, among them treatment with 
imiquimod. Our aim is to clarify the efficacy and safety of the use of topical 
imiquimod cream in the treatment of extramammary Paget disease.
In this article the current literature in Pubmed and Scopus on this topic is 
reviewed. 
According to the literature the topical use of imiquimod can be used as 
first-line treatment in different dosages and durations with excellent results, 
reaching a 87.5% cure rate with rare complications. The available evidence 
is currently limited to case reports and a single case series, but is definitely 
in favor of imiquimod use as an alternative treatment for extramammary 
Paget disease.
KEY woRDS: extramammary, Paget disease, imiquimod, vulva, scrotum, 
genital neoplasia 
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Demographics No. patients/ 
Total (%)(%)
Age, in years* 69 (48-90)
Nr of patients 31
Medical History
Comorbidities 4/31 (12.9)
Onset of the disease, in years* 2 (0.2-15)
Major diameter of the lesion, in cm* 5 (1.5-10)
Symptoms
pruritus 21/27 (77.8)
erythematous plaque 18/27 (66.7)
pain 5/27 (18.5)
local hypopigmentation 1/27 (3.7)
indolent eczematous eruption 1/27 (3.7)
Local lymphadenopathy 0/31
Initial treatment applied
topical cream treatment 10/31 (32.3)
none 8/31 (25.8)
combination of treatments 7/31 (22.6)
local excision 6/31 (19.3)
Location of the lesions
vulva 27/31 (87.1)




Clinical features of imiquimod treatment
Applied dose
3 times per week 23/31 (74.2)
2 times per week 3/31 (9.7)
daily 4/31 (12.9)
Duration of treatment, in weeks* 14 (2-32)
Complications
pain 12/31 (38.7)
skin erosion 12/31 (38.7)




flu like symptoms 3/31 (9.7)
Outcomes
Healing 24/31 (77.4)
Follow up, in months* 10.5 (0.5-36)
Relapse 6/31 (19.3)
Treatment of relapse
surgical excision 4/31 (12.9)
prolungation of imiquimod 
treatment
2/31 (6.5)
radiation therapy 1/31 (3.2)
photodynamic therapy 1/31 (3.2)
options include topical agents and localized radia-
tion therapy, electrodessication and curettage, laser, 
photodynamic therapy with aminolevulinic acid, and 
local chemotherapy with bleomycin, and 5-fluoroura-
cil (5-FU) (12,13).
Imiquimod is an imidazoquinolin derivative with 
immunomodulating properties. It was approved by 
the FDA in 1997. It binds to toll-like receptor-7 of an-
tigen-presenting cells, such as macrophages, mono-
cytes, and dendritic cells, and promotes the activation 
and release of numerous cytokines, including IFN-α, 
TNF-α and several interleukins (14). In addition to its 
antiviral, antiproliferative, and antiangiogenic prop-
erties, imiquimod enhances the activity of T-cells and 
the aforementioned cytokines activate NK and cy-
totoxic cells. It is also involved with the migration of 
Langerhans cells to the lymph nodes and the prolif-
eration of B-lymphocytes, and consequently induces 
apoptosis and obstructs the angiogenesis of the tu-
mor (14). Imiquimod is the drug of choice for external 
genital warts, actinic keratosis, superficial basal cell 
carcinoma, vulvar intraepithelial neoplasia (VIN), and 
vaginal intraepithelial neoplasia (VaIN) (15), but it can 
also be used as a local treatment of extramammary 
Paget disease. It was first used this way by Zampogna 
et al. in 2002 (46). Imiquimod is locally administered, 
mostly in regimens of 5% cream and different appli-
cation schemata. Common side effects of imiquimod 
include local skin irritation, erythema, and erosion. 
Less common side effects are post-inflammatory hy-
per- or hypopigmentation, flu-like symptoms, nau-
sea, and vomiting (16).
The aim of our study is to review the published 
articles on the efficacy and safety of the use of topical 




We performed an electronic, systematic search of 
PubMed (until 23 April 2013) and Scopus (until 23 April 
2013). The search strategy applied to both PubMed 
and Scopus databases, consisted of the combination 
of the following key words: (Paget disease OR Paget) 
AND imiquimod. In order to reveal additional studies, 
a manual search was also performed in the references 
of the selected studies.
Study selection criteria
Studies reporting data on the application of im-
iquimod cream in cases of extramammary Paget 
disease were included in the review. Abstracts from 
Table 1. Main characteristics and outcomes of the 
female patients with extramammary Paget disease
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scientific conferences, editorials, and animal studies 
were excluded. Studies published in languages oth-
er than English, French, Italian, Spanish, German, or 
Greek were not included.
RESulTS
During the literature search in PubMed and Sco-
pus, a total of 45 and 122 search results  were retrieved 
respectively. Among these, 36 studies (35 case reports 
and 1 case series) were identified as eligible for inclu-
sion in our review. One additional study was identi-
fied through manual reference search (Figure 1).
CASE REPoRTS 
In Table 1 we summarize the existing data from fe-
male patients included in case reports on cases of ex-
tramammary Paget disease; data for 30 patients from 
21 reports were available (1-7,9,11,14,16-25).
The median age of the 30 women with extrama-
mmary Paget’s disease was 69, ranging from 48 to90 
years. Four out of 30 had comorbidities. The median 
onset of the disease was 2 years (ranging from 0.2 
to 15 years), and the median major lesion diameter 
was 5 cm (1.5-10 cm). The main symptoms included 
pruritus (77.8%), erythematous plaque (66.7%), pain 
(18.5%), local hypopigmentation (3.7%), and indolent 
eczematous eruption (3.7%). None of the patients 
had local lymphadenopathy. The main location of the 
disease was the vulva in 90% of the patients, followed 
by the perianal area in 30%, the gluteus in 13.3%, the 
thorax 3.3% and the axilla in 3.3%. The disease was 
initially treated with topical cream in 33.3% of the 
patients, a combination of treatment in 23.3%, local 
excision in 20.0%, while 23.3% patients received no 
intervention. The application of imiquimod ranged 
from daily (13.3%) to 3 times or (76.7%) 2 times per 
week (10.0%), and was given for an average of 14 
weeks ranging from 2-32 weeks depending on the 
symptoms and complications. The most common 
complications after the use of imiquimod included 
pain in 40.0% of the patients, skin erosion in 40.0%, 
local irritation in 33.3%, erythema in 16.6%, pruritus 
in 13.3%, and flu-like symptoms in 10.0%, while 23.3% 
had no complications. Eighty per cent of patients 
were healed. During the median follow-up period of 
10.5 months (0.5-36 months), 20.0% of the patients 
relapsed. These patients were treated with surgical 
excision, renewed of imiquimod treatment, or radia-
tion or photodynamic therapy.
In Table 2 we summarize the available data from 
16 male patients included in 16 case reports of extra-
mammary Paget disease (8,16,26-39).
Demographics No. patients/
Total (%)
Age, in years* 70 (57-82)
Nr of patients 16
Medical History
Comorbidities 6/16 (37.5)
Onset of the disease, in years* 4 (0.2-20)
Major diameter of the lesion, in cm* 5 (1.5-9)
Symptoms
pruritus 7/16 (41.2)
erythematous plaque 10/16 (43.8)
pain 3/16 (18.7)
superficial ulcers 1/16 (6.3)
local hypopigmentation 1/16 (6.3)





topical cream treatment 6/16 (37.5)
local excision 3/16 (18.7)
combination of treatments 1/16 (6.3)
Location of the lesions
scrotum 13/16 (81.3)
penile shaft 8/16 (50)
perianal area 4/16 (25)
axilla 1/16 (6.3)
thorax 1/16 (6.3)
Clinical features of imiquimod treatment
Applied dose
3 times per week 11/16 (68.8)
daily 6/16 (37.5)




skin erosion 4/16 (25)
pain 4/16 (25)
local irritation 3/16 (18.7)
flu like symptoms 1/16 (6.3)
Outcomes
Healing 14/16 (87.5)
Follow up, in months* 12 (5-24)
Relapse 2/16 (12.5)
Treatment of relapse
radiation therapy 2/16 (12.5)
photodynamic therapy 1/16 (6.3)
Table 2. Main characteristics and outcomes of the 
male patients with extramammary Paget disease
Abbreviation: cm = centimeters, nr = number
* median (range).
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The median age of the male patients was 70, rang-
ing from 57 to 82 years. Six out of 16 patients had co-
morbidities. The median onset of the disease was 4 
years (ranging from 0.2 to 20 years), and the median 
major lesion diameter was 5 cm (1.5-9 cm). The main 
symptoms included pruritus (41.2%), erythematous 
plaque (43.8%), pain (18.7%), local hypopigmenta-
tion (6.3%), indolent eczematous eruption (6.3%), 
superficial ulcers (6.3%), and fever (6.3%). None of 
the patients had local lymphadenopathy. The main 
location of the disease was the scrotum in 81.3%, the 
penile shaft in 50.0%, perianal area in 25.0%, the tho-
rax in 6.3%, and the axilla in 6.3%. The disease was ini-
tially treated with topical cream in 37.5%, a combina-
tion of treatment in 6.3%, and local excision in 18.7%, 
while 41.2% had no intervention. The application of 
imiquimod ranged from daily (37.5%) to 3 times per 
week (68.8%) and was given for an average of 16 
weeks, ranging from 6-36 weeks depending on the 
symptoms and the complications. The most common 
complications after imiquimod treatment included 
pain in 25.0%, skin erosion in 25.0%, local irritation 
in 18.7%, erythema in 56.3%, and flu-like symptoms 
in 6.3% of the patients, while 25.0% had no compli-
cations. 87.5% of patients were healed. During the 
median follow-up period, which was 12 months (5-24 
months), 12.5% of the patients relapsed. These pa-
tients were treated with surgical excision, radiation, 
or photodynamic therapy.
CASE SERIES 
We also identified a single case series that included 
fourteen patients with extramammary Paget disease 
(40). The study included 14 patients with a mean age 
of 73 years (range: 58–91). The onset of the symptoms 
was 34.7 months on average. The majority of the pa-
tients (13 out of 14) presented with lesions located 
in the genital region. The mean size of the lesion was 
6.7 cm (range: 2–15). 47.0% of the lesions had previ-
ously been treated. As first-line treatment, the topical 
use of imiquimod was applied in 8 out of 14 patients. 
The most frequent imiquimod dosage was 3 times 
weekly for at least 3 months. The mean duration of 
imiquimod treatment was 5.5 months (range: 2–12). 
Residual disease after treatment was present in 5 out 
of 14 patients.
DISCuSSIon
There is limited data regarding the presentation of 
extramammary Paget disease and its possible man-
agement with local application of imiquimod cream.
The available evidence shows that its presentation 
varies in location, and mainly presents in the seventh 
decade of life. The median onset of the disease was 2 
years in women and 4 years in men, a difference that 
can perhaps be attributed to more frequent screen-
ing of women for genital area diseases. The workup 
includes: physical examination, skin examination, 
lymph nodes palpation, PAP smear plus or minus 
Figure 1. Flow chart of the selection process of articles eligible for inclusion in the 
review. * The majority of studies were found in both databases 
Potentially relevant articles 
retrieved from Pubmed 
and Scopus 
(m=167)
Articles selected for further 
evaluation after first 
screening of title and 
abstract (n=99) 
37 individual articles qualifying for 
inclusion in our review 
68 studies were excluded as irrelevant to the 
review based on their title or abstract*
Articles excluded after detailed screening according to specific 
criteria (n=62) 
Review articles (n=48) 
Articles not referring to extramammary Paget disease (n=10) 
Commentaries (n=2) 
Short surveys (n=1) 
Articles written in languages not included (n=1) 
An additional study 
identified through 
manual searching of 
bibliographies of 
relevant articles 
Figure 1. Flow chart of the selection process of articles eligible for inclusion in the review. 
* The majority of studies were found in both databases
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colposcopy, rectal examination, and breast examina-
tion. Mammogram, ultrasound, and colonoscopy are 
necessary in order to exclude mammary, genitouri-
nary, or gastrointestinal cancer (41). The main symp-
toms are local and include pruritus, erythema, pain, 
burning, hypopigmentation (well-defined hypopig-
mented to pink plaque), and indolent eczematous 
eruption. Local lymphadenopathy was not found 
in patients with extramammary Paget disease (1-
9,11,14,16-39,42). The differential diagnosis includes 
Bowen’s disease, psoriasis, and dermatitis, which 
could delay the diagnosis (9,32). Patients usually have 
a history of topical use of corticosteroids, antibiot-
ics, antifungals, and pimecrolimus 1% cream (11). It 
should be noted that punch biopsy is very significant 
for the diagnosis, as it can clarify whether there is any 
underlying malignancy (2,5,11,16-20,22,29,34-36,42). 
The histological findings include hyperkeratosis, 
parakeratosis, acanthosis, difuse infiltration by cells 
with abundant pale cytoplasm, and vacuolated nu-
clei (Paget’s cells) throughout the epidermis (43). Im-
munohistochemistry is positive for carcinoembryonic 
antigen (CEA), cytokeratin (CK7), cytokeratin (CK18), 
and epithelial membrane antigens, and negative for 
S-100 protein(44).
Local application of imiquimod (on the lesion 
and 1-2 cm around it) nightly or up to 2 or 3 times 
weekly for a median period of 4 months is suggested. 
Fusidic acid ointment could be used locally to loosen 
the small crusts (1,21). Various dosing regiments have 
been suggested to achieve histopathologic clearance 
(1-9,11,14,16,18,19,21-23,26-31,33-38), but mainte-
nance treatment is clearly indicated. In our review, 
we tried to clarify the role of imiquimod in the partial 
or complete recovery in patients with extramammary 
Paget disease. The evidence from case reports and 
case series suggested that the majority of patients 
with extramammary Paget disease can be cured with 
imiquimod (80% of the women and 87.5% of the 
men). Complications are relatively common, but they 
are mainly local and include local irritation, erosion, 
and tenderness, amd rarely flu like symptoms, nau-
sea, and diarrhea only rarely (1-3,5,7,9,11,14,16,17,21-
24,26-32,34-39,42). The management of complica-
tions includes temporarily terminating imiquimod 
use and local application of lidocaine 3% cream (11). 
Recurrence rate is up to 43%, and can usually be 
treated with wide local excision, radiation, or photo-
dynamic therapy (40).
The major advantage of imiquimod is that it can 
be used in the treatment of elderly patients or in pa-
tients that are poor surgical candidates in general 
(14,25,26,30). As it can also offer good cosmetic re-
sults, it can be suggested to patients who are afraid 
of or opt out of surgical management, as it can be ap-
plied locally(5,24).
ConCluSIon
Imiquimod could be an effective alternative con-
servative treatment option for extramammary Paget 
disease though the use would be off-label. The avail-
able evidence is currently limited to case reports and 
studies with different study designs and patients 
characteristics. More data  regarding the dose, com-
plications, and follow-up is necessary. Randomized 
controlled trials could determine the safety, dose re-
lated issues, and efficacy of the treatment, especially 
after long follow-up periods. It should be noted that 
continuous clinical monitoring following treatment 
of extramammary Paget disease is essential inde-
pendently of the therapeutic options, in order to 
early diagnose possible recurrences. Gynaecologists, 
urologists, and dermatologists should be aware of 
the disease and the possible role of imiquimod in its 
management.
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